No Data
No Data
T2 Biosystems Anticipates Breakthroughs and Extends NASDAQ Compliance
T2 Biosystems Targets Commercial Launch Of T2Lyme Panel In Q3 - Quick Facts
T2 Biosystems Unveils T2Lyme Launch Plans and Provides Additional Business Updates
Anticipates commercial launch of the T2Lyme Panel in the third quarter of 2024LEXINGTON, Mass., March 20, 2024 (GLOBE NEWSWIRE) -- T2 Biosystems, Inc. (NASDAQ:TTOO) (the "Company"), a leader in the
T2 Biosystems to Host Investor Call on March 20, 2024 to Unveil Its T2Lyme Launch Plans and Provide Additional Business Updates
LEXINGTON, Mass., March 19, 2024 (GLOBE NEWSWIRE) -- T2 Biosystems, Inc. (NASDAQ:TTOO) (the "Company"), a leader in the rapid detection of sepsis-causing pathogens and antibiotic resistance genes, t
T2 Biosystems Revolutionizes Infection Detection Efficiency
T2 Biosystems Announces New Publication Highlighting the Clinical Benefits and Performance of the T2Resistance Panel
Study demonstrates T2Resistance Panel utilization enables faster targeted therapy based on direct-from-blood detection of resistance genesLEXINGTON, Mass., March 18, 2024 (GLOBE NEWSWIRE) -- T2 Bios
No Data